Alpha-1 Antitrypsin Deficiency clinical trials
17 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
- A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- Gene Therapy for Alpha 1- Antitrypsin Deficiency
- Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
- A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
- Alpha-1 Research Registry
- Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- PiMZ Longitudinal Cohort (PiMZ Logic)
- Role of Genetic Factors in the Development of Lung Disease
- Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
- Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
- Alpha-1 Foundation DNA and Tissue Bank
- Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Alpha-1 Antitrypsin Deficiency” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.